DYAI
Dyadic International, Inc.
There isn't enough reported data to score DYAI yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
DYAI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
DYAI's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DYAI PE Valuation
DYAI has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DYAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DYAI's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
DYAI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.21 | -$0.02 |
| Q1 2026 | -$0.21 | -$0.01 |
| Q4 2025 | -$0.23 | -$0.03 |
| Q3 2025 | -$0.24 | -$0.02 |
| Q2 2025 | -$0.19 | +$0.08 |
| Q1 2025 | -$0.20 | +$0.07 |
| Q4 2024 | -$0.20 | +$0.03 |
| Q3 2024 | -$0.22 | +$0.01 |
DYAI is still losing money, but far less than before: $0.21 per share over the past year, against $0.47 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DYAI on earnings quality, reporting a profit while its opponent remains loss making.
DYAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $961.1K | -0.6% |
| Q1 2026 | $1.1M | +182% |
| Q4 2025 | $565.5K | -31% |
| Q3 2025 | $1.2M | -41% |
| Q2 2025 | $966.6K | +150% |
| Q1 2025 | $393.6K | +18% |
| Q4 2024 | $817.4K | +19% |
| Q3 2024 | $2M | +393% |
DYAI's revenue has slid since its 2024 peak: $961,138 last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -214% | -35 points |
| Q1 2026 | -171% | +338 points |
| Q4 2025 | -272% | -84 points |
| Q3 2025 | -165% | -155 points |
| Q2 2025 | -179% | +350 points |
| Q1 2025 | -509% | +126 points |
| Q4 2024 | -187% | +129 points |
| Q3 2024 | -10% | +423 points |
DYAI's operating margin was −214% last quarter, down 35 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DYAI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DYAI on profitability, with a higher operating margin.
DYAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$1.8M | -$1.7M |
| Q1 2026 | -$2M | -$13.6K |
| Q4 2025 | -$1.8M | -$1.1M |
| Q3 2025 | -$1.9M | -$1.7M |
| Q2 2025 | -$130K | +$1.8M |
| Q1 2025 | -$1.9M | -$836.8K |
| Q4 2024 | -$696.4K | +$227K |
| Q3 2024 | -$201.1K | +$1.8M |
DYAI has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DYAI on cash generation, producing positive trailing cash flow while its opponent burns cash.
DYAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +40.7K shares |
| 1 year | +21% | +6.3M shares |
| 3 years | +26% | +7.6M shares |
| 5 years | +32% | +8.8M shares |
| Available history | +34% | +9.3M shares |
DYAI has 36M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over DYAI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DYAI Net Leverage
DYAI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
DYAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.7 | Neutral |
| Stochastic | 2.7 | Oversold |
DYAI's weekly RSI is 32 (neutral) and its Stochastic is 3 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DYAI PE vs Healthcare Sector
DYAI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DYAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.40 | 13% below |
| 20 week MA | $0.66 | 47% below |
| 50 week MA | $0.77 | 55% below |
| 100 week MA | $0.98 | 64% below |
| 200 week MA | $1.30 | 73% below |
DYAI is in a downtrend: it's below all five of its weekly moving averages, and 73% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over DYAI on trend strength, trading above more of its moving averages.
DYAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.28 | $5.57 | +5.5% |
| 2021 | $5.57 | $4.11 | -26% |
| 2022 | $4.11 | $1.37 | -67% |
| 2023 | $1.37 | $1.61 | +18% |
| 2024 | $1.61 | $1.96 | +22% |
| 2025 | $1.96 | $0.95 | -52% |
| 2026 YTD | $0.95 | $0.35 | -63% |
DYAI has finished lower in three of the last six years. It's down 63% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over DYAI on returns for 2026, with the stronger performance.